What is pathophysiology of Prostate cancer?

Cale est sa fisiopatologia de su tumore a sa prostata?

Sa fisiopatologia de su tumore a sa prostata si riferit a sos mecanismos e protzessos sutastantes chi batint a s'isvilupu e a sa progressione de sa maladia.

Su tumore a sa prostata est unu tumore malignu chi naschet dae sas tzèllulas de sa ghiandula prostàtica, chi est un'òrganu minore a forma de noce chi s'agatat in suta de sa buca in sos òmines.

Sa ghiandula de sa prostata produit unu lìcuidu seminadu, chi nutrit e carrat su sèmene.

Sa càusa giusta de su tumore a sa prostata no est cumprèndida de su totu, ma paritzos fatores sunt nòdidos pro crèschere su riscu de isvilupare sa maladia.

Custos includent s'edade, s'istòria familiare, sa ratza e tzertas mutatziones genèticas.

Su tumore a sa prostata est prus comunu in sos òmines prus betzos, cun sa majoria de sos casos chi si manifestant in sos òmines cun prus de 65 annos.

In prus, is ominis cun una stòria familiari de cancru a sa prostata funt a arriscu prus mannu, cummenti is ominis afro-americanus e is ominis de orìgini caraìbica.

Sa fisiopatologia de su tumore a sa prostata interessat sa crèschida e sa divisione non controllada de sas tzèllulas a intro de sa ghiandula prostàtica.

Custu podet acontèssere pro more de mudatziones genèticas chi batint a s'everexpressada de tzertos fatores de crèschida o a s'inattivatzione de genes supressores de tumores.

Custas mudatziones podent resurtare in sa crèschida non regulada de sas tzèllulas, giughende a sa formatzione de unu tumore.

Cando su tumore creschet, podet invàdere sos tessidos e òrganos a curtzu, comente a sa buca de s'ischèntzia, su rettu e sos nodos lìmpicos a curtzu.

In carchi casu, sas tzèllulas tumorales si podent ischirriare dae su tumore primàriu e si podent ispainare a àteras partes de su corpus pro mèdiu de su flussu sanguignu o de su sistema limfàticu, unu protzessu connotu comente metastasi.

Una borta chi su tumore s'est ispartu, podet èssere prus difìtzile de tratare.

Su tumore a sa prostata podet èssere influentzadu fintzas dae fatores ormones, in particulare s'ormone androgènicu testosterone.

Su testosterone podet istimulare sa crèschida de sas tzèllulas tumorales de sa prostata, e medas tratamentos pro su tumore a sa prostata punnant a reduire sos livellos de custu ormone o a blocare sos efetos suos.

In resumu, sa fisiopatologia de su tumore a sa prostata interessat sa crèschida e sa divisione non controllada de sas tzèllulas a intro de sa ghiandula prostàtica, chi podet èssere influentzada dae fatores genèticos, ormones e ambientales.

Cumprèndere sos mecanismos sutastantes de sa maladia est fundamentale pro isvilupare tratamentos eficatzes e megiorare sos resurtados pro sos malàidos cun tumore a sa prostata.

['Referèntzias']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Zobniw CM, Causebrook A, Fong MK: Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Res Rep Urol. 2014, 6 (): 97-105.

Lim HY, Agarwal AM, Agarwal N, Ward JH: Recurrent epistaxis as a presenting sign of androgen-sensitive metastatic prostate cancer. Singapore Med J. 2009, 50 (5): e178-80.

Kohli M, Qin R, Jimenez R, Dehm SM: Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol. 2012, 2012 (): 781459.

Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995, 1 (9): 944-9.

Msaouel P, Nandikolla G, Pneumaticos SG, Koutsilieris M: Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer. Expert Opin Investig Drugs. 2013, 22 (11): 1385-400.

Kotani K, Sekine Y, Ishikawa S, Ikpot IZ, Suzuki K, Remaley AT: High-density lipoprotein and prostate cancer: an overview. J Epidemiol. 2013, 23 (5): 313-9.

Jadvar H: Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging. , 8 (2): 56-64.

['Disclaimer: mèdicu']

['Custu giassu est fatu po istudiare e informae sa zente e non est unu giassu de consultatzione o de azudu.']

['Sa informassione frunida no est de impreare pro diagnosticare o curare unu problema de salude o una maladia, e sos chi chircant consìgios mèdicos personales si depent cuntatare cun unu mèdicu autorizadu.']

["S'arricordaus ca sa retza neurali chi creat rispostas a is pregontas est imperfeta candu si chistionat de nùmerus, po nai su nùmeru de personas chi tenint una maladia."]

["Chirca semper su parre de su dotore tuo o de un'àteru dotore cualificadu pro cale si siat cunditzione mèiga. No disconnoscas mai su parre de unu professionista mèigu o non bi tardes a l'agatare pro carchi cosa chi as lèghidu in custu situ. Si tenes pensamentos de tènnere un'emergèntzia mèiga, telefona a su 911 o bae a su pronto soccorsu prus acanta."]

['Disclaimer: deretu de autore']

['Sa Digital Millennium Copyright Act de su 1998, 17 U.S.C. § 512 (sa DMCA) donat unu recursu a is propietàrius de deretus de autori chi pensant chi unu materiali chi aparit in Internet ofendet is deretus insoru assuta de sa lei de su deretu de autori de is IUA. ']

["Si creis de bona fidi chi calicunu cuntènniu o materiale postu a disponimentu in su giassu o in is servìtzios nostros at ofesu is deretus de autore tuos, tui (o s'agenti tuo) nos podes imbiare una comunicatzioni domandendi de nde bogare su cuntènniu o su materiale, o de nde blocare s'atzessu."]

['Sos annùntzios depent èssere imbiados pro iscrittu pro mèdiu de posta eletrònica (càstia sa setzione "Cuntatu" pro s\'indiritzu de posta eletrònica). ']

["Sa DMCA recheret chi sa notìfica tua de sa presunta violatzione de copyright incluat sas informatziones sighentes: (1) descritzione de s'òpera amparada dae copyright chi est ogetu de sa presunta violatzione; (2) descritzione de su chi si narat chi est unu cuntènnidu chi diat pòdere èssere istadu violadu e informatziones bastantes pro nos permìtere de localizare su cuntènnidu; (3) informatziones pro ti cuntatare, intre cales s'indiritzu tuo, su nùmeru de telèfono e s'indiritzu de posta eletrònica; (4) una decraratzione tua pro nàrrere chi tenes bona fide chi su cuntènnidu de sa manera chi ses lamentende non est autorizadu dae su mere de su copyright, dae s'agente suo o dae cale si siat lege."]

["5) una decraratzione firma tua, suta pena de perjuria, chi is informatziones in sa notìfica sunt acuradas e chi tenes s'autorizatzione pro aplicare is deretos de autore chi sunt istados violados; "]

['e (6) una firma fìsica o eletrònica de su mere de su deretu de autore o de una persone autorizada a agire a nùmene suo. ']

['Si non ponis totu is informatzionis de prima podit essi chi su protzedimentu ti siat tardau.']

['Contatu']

['Manda·nos una mail cun cale si siat dimanda o sugerimentu.']

What is pathophysiology of prostate cancer?

The pathophysiology of prostate cancer refers to the underlying mechanisms and processes that lead to the development and progression of the disease.

Prostate cancer is a malignant tumor that arises from the cells of the prostate gland, which is a small, walnut-shaped organ located below the bladder in men.

The prostate gland produces seminal fluid, which nourishes and transports sperm.

The exact cause of prostate cancer is not fully understood, but several factors are known to increase the risk of developing the disease.

These include age, family history, race, and certain genetic mutations.

Prostate cancer is more common in older men, with the majority of cases occurring in men over the age of 65.

Additionally, men with a family history of prostate cancer are at an increased risk, as are African American men and men of Caribbean descent.

The pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland.

This can occur due to genetic mutations that lead to the overexpression of certain growth factors or the inactivation of tumor suppressor genes.

These mutations can result in the unregulated growth of cells, leading to the formation of a tumor.

As the tumor grows, it can invade nearby tissues and organs, such as the bladder, rectum, and nearby lymph nodes.

In some cases, cancer cells can break away from the primary tumor and spread to other parts of the body through the bloodstream or lymphatic system, a process known as metastasis.

Once the cancer has spread, it can be more difficult to treat.

Prostate cancer can also be influenced by hormonal factors, particularly the androgen hormone testosterone.

Testosterone can stimulate the growth of prostate cancer cells, and many treatments for prostate cancer aim to reduce the levels of this hormone or block its effects.

In summary, the pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland, which can be influenced by genetic, hormonal, and environmental factors.

Understanding the underlying mechanisms of the disease is crucial for developing effective treatments and improving outcomes for patients with prostate cancer.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.